C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
AKAN Equity

AKAN

OTCMKTS · AKAN

$1.33
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
35/100 composite
Fundamentals24
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Akanda Corp earns a Neutral rating with three-out-of-five conviction, reflecting a composite score in the mid-30s and a sharply uneven pillar profile. Regulatory is the strongest contribution at 49, supported by a neutral jurisdiction posture and a strong enforcement subscore. Market ranks second at 40 despite the absence of an available quote, limiting confirmation from institutional pricing feeds. Editorial contributes 30, consistent with no recent newsroom or brief activity in CIN newsroom coverage. Fundamentals trails at 24, as revenue momentum is overwhelmed by negative profitability, limited cash-runway support, and a stretched financial condition. The resulting band remains Neutral rather than Overweight because the regulatory profile offsets, but does not reverse, weak operating economics.

Licensed fundamentals data show year-over-year revenue growth of approximately 22%, producing the company’s strongest fundamental subscore at nearly 72. That expansion has not translated into viable unit economics: gross margin stands near negative 60%, while operating margin is below negative 1,300%. EBITDA remains negative at roughly $4.7 million, and the cash-burn ratio is about 0.87, leaving the cash-runway subscore at only 15. A market capitalization of approximately $5.4 million also contributes no support under the size tier. Primary regulatory filings show no recorded regulatory events during either the latest 90-day or 180-day windows and no enforcement hits. However, no latest filing date is available, which holds the cadence subscore at 25 even as the enforcement subscore reaches 80. The data therefore identify regulatory standing, not financial execution, as the principal source of rating support.

The forward catalyst rests squarely on the regulatory pillar. A newly dated primary regulatory filing would establish observable cadence, improve transparency around the current stretched condition, and reinforce the clean enforcement record already carrying the highest subscore in the framework. That development would also provide a firmer basis for assessing whether revenue growth can progress toward less punitive margins without overstating the significance of top-line expansion. Editorial activity or restored pricing visibility would add context, but neither matches the regulatory pillar’s current contribution. The single most important signal to watch is the appearance of a timely primary regulatory filing that lifts cadence while preserving the absence of enforcement hits.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
1A, 1B LEAROYD ROAD, NEW ROMNEY, X0, TN28 8XU
Phone
442034889514
Auditor
with our independent registered public accounting firm
SEC CIK
1888014
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$5.4M
Enterprise value
$19.1M
Price to book
2.21
Price to sales
20.83
EV / EBITDA
-0.80
Revenue (TTM)
$258K
Gross profit (TTM)
$-156K
EBITDA
$-4.7M
Operating margin
-1353.3%
Profit margin
0.0%
Rev growth YoY
21.9%
Return on equity
-60.9%
Return on assets
-44.1%
EPS (TTM)
$-15065.55
Shares outstanding
0.5M
Insider ownership
0.6%
Institutional ownership
1.9%
Beta
14.16
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for AKAN (AKAN)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for AKAN (AKAN), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for AKAN are maintained by Cannabis Investor News and refreshed throughout the trading day.